A pilot double-blind randomized placebo-controlled crossover pharmacodynamic study of the centrally active aminopeptidase A inhibitor, firibastat, in hypertension

Conclusion: In patients with hypertension, a 4-week treatment with firibastat, tended to decrease daytime SBP relative to placebo. Firibastat did not modify the activity of the systemic renin–angiotensin system These results have justified designing a larger, powered trial of longer duration to fully assess its safety and effectiveness. Clinical trial registration: http://www.clinicaltrials.gov. NCT02322450.
Source: Journal of Hypertension - Category: Cardiology Tags: ORIGINAL PAPERS: Treatment Source Type: research